Fingerprint
Dive into the research topics of 'Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically